MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

WST · NYSE

West Pharmaceutical Services, Inc.

Health Care · Medical/Dental Instruments

Reference price$337.00As of Jul 28, 2026
Market capitalization$23.72B
52-week range$223.83–$386.00
S&P 500 portfolio weight0.04%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$365.00+8.3% vs. reference
Average$402.75+19.5% vs. reference
High$447.00+32.6% vs. reference
8 Buy1 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableSep 2026
Consensus EPS$2.195 estimates
Expected range$2.18–$2.21Low to high EPS
Dec 2026$8.94Street EPS consensus
Dec 2027$9.87Street EPS consensus
Dec 2028$11.04Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+6.3% YoY$3.07B$2.89B
Operating income$0.58B$0.57B
Net income$0.49B$0.49B
Operating cash flow$0.75B$0.65B
Capital expenditures($0.29B)($0.38B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

STERIS' Q1 Earnings on Deck: What's in Store for the Stock?

Zacks

MMED Gets Medicare Coverage for Flex and Broadens Diabetes Care Access

Zacks

Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.